Advanced Enzyme Technologies Ltd vs Remedium Lifecare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Advanced Enzyme Technologies Ltd is ₹ 355.6 as of 06 May 15:30 . The P/E Ratio of Advanced Enzyme Technologies Ltd changed from 23.8 on March 2025 to 29.1 on March 2024 . This represents a CAGR of 4.10% over 5 yearsThe P/E Ratio of Remedium Lifecare Ltd changed from 36.4 on March 2025 to 0 on March 2024 . This represents a CAGR of -100.00% over 5 years The Market Cap of Advanced Enzyme Technologies Ltd changed from ₹ 3120 crore on March 2025 to ₹ 3885 crore on March 2024 . This represents a CAGR of 4.49% over 5 yearsThe Market Cap of Remedium Lifecare Ltd changed from ₹ 73.38 crore on March 2025 to ₹ 0 crore on March 2024 . This represents a CAGR of -100.00% over 5 years The revenue of Advanced Enzyme Technologies Ltd for the Dec '25 is ₹ 191.66 crore as compare to the Sep '25 revenue of ₹ 194.81 crore. This represent the decline of -1.62% The revenue of Remedium Lifecare Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 114.31 crore. This represent the decline of -100% The ebitda of Advanced Enzyme Technologies Ltd for the Dec '25 is ₹ 69.07 crore as compare to the Sep '25 ebitda of ₹ 70.34 crore. This represent the decline of -1.81% The ebitda of Remedium Lifecare Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 10.62 crore. This represent the decline of -100% The net profit of Advanced Enzyme Technologies Ltd changed from ₹ 34.98 crore to ₹ 43.18 crore over 7 quarters. This represents a CAGR of 12.79% The net profit of Remedium Lifecare Ltd changed from ₹ -2.05 crore to ₹ 0 crore over 4 quarters. This represents a CAGR of -100.00% The Dividend Payout of Advanced Enzyme Technologies Ltd changed from 14.16 % on March 2021 to 56.81 % on March 2025 . This represents a CAGR of 32.03% over 5 yearsThe Dividend Payout of Remedium Lifecare Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Limited (AETL) is largest Indian enzyme company that transformed business globally in the manufacturing and sale of enzymes.
The Company was incorporated, as a Private Company on March 15, 1989 as 'Advanced Biochemicals Private Limited' in Maharashtra.
It thereafter converted the status into a Public Company and the name of the Company was changed to Advanced Biochemicals Limited on May 28, 1992 and further was changed to Advanced Enzyme Technologies Limited via fresh Certificate of Incorporation at RoC, Mumbai on August 19, 2005. In 2011, the company took over Cal-India Foods International, giving the company direct presence in USA. In 2012, the company took over Advanced Supplementary Technologies Corporation for consolidating its presence in USA. Advanced Enzyme Technologies Limited came out with its Initial Public Offer (IPO) of 4,594,875 Equity shares of Rs 10 each at an issue price of Rs 896 per Equity share ( Rs 810 per Equity share for eligible employees), consisting of fresh issue of 560,405 Equity shares and an Offer for Sale of 4,034,470 Equity shares by Selling Shareholders.

About Remedium Lifecare Ltd

Remedium Lifecare Limited (Formerly known as 'Roxy Exports Limited) was incorporated in February 19, 1988.
Consequent to change in the business activities and accordingly, in order to keep the name of the Company in consonance with the new business activities, the Company changed its name from 'Roxy Exports Limited' to 'Remedium Lifecare Limited' vide a fresh Certificate of Incorporation on November 6, 2020 issued by the Registrar of Companies. The Company being a pharmaceutical company is aligned across two business verticals viz. products and services.
Products business comprises trading and sale of APIs and Intermediates to innovator and generic pharmaceutical players in both domestic and international markets including the regulated markets. Apart from this, the Company is engaged in the business of trading in Advanced Pharmaceutical Intermediates, Active Pharmaceutical Ingredients (API's) and other pharma products used viz.

FAQs for the comparison of Advanced Enzyme Technologies Ltd and Remedium Lifecare Ltd

Which company has a larger market capitalization, Advanced Enzyme Technologies Ltd or Remedium Lifecare Ltd?

Market cap of Advanced Enzyme Technologies Ltd is 3,980 Cr while Market cap of Remedium Lifecare Ltd is 38 Cr

What are the key factors driving the stock performance of Advanced Enzyme Technologies Ltd and Remedium Lifecare Ltd?

The stock performance of Advanced Enzyme Technologies Ltd and Remedium Lifecare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Advanced Enzyme Technologies Ltd and Remedium Lifecare Ltd?

As of May 6, 2026, the Advanced Enzyme Technologies Ltd stock price is INR ₹355.6. On the other hand, Remedium Lifecare Ltd stock price is INR ₹0.44.

How do dividend payouts of Advanced Enzyme Technologies Ltd and Remedium Lifecare Ltd compare?

To compare the dividend payouts of Advanced Enzyme Technologies Ltd and Remedium Lifecare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.